Cellectis Valuation Multiples

Cellectis Overview

About Cellectis

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Founded

2000

HQ

Employees

222

Website

cellectis.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $74M

EBITDA: ($49M)

EV

$324M

Valuation Multiples

Multiples.vc

Start free trial

Cellectis Financials

Cellectis reported last 12-month revenue of $74M and negative EBITDA of ($49M).

In the same LTM period, Cellectis generated $74M in gross profit, ($49M) in EBITDA losses, and had net loss of ($88M).

Cellectis P&L

In the most recent fiscal year, Cellectis reported revenue of $79M and EBITDA of ($40M).

Cellectis expects next 12-month revenue of XXX and NTM EBITDA of XXX

Cellectis Stock Performance

Cellectis has current market cap of $442M, and enterprise value of $324M.

Cellectis' stock price is $4.39.

Cellectis Valuation Multiples

Cellectis trades at 4.4x EV/Revenue multiple, and (6.6x) EV/EBITDA.

Cellectis Financial Valuation Multiples

As of April 18, 2026, Cellectis has market cap of $442M and EV of $324M.

Equity research analysts estimate Cellectis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Cellectis has a P/E ratio of (5.0x).

Cellectis Margins & Growth Rates

Cellectis' revenue in the last 12 month grew by 7%.

Cellectis' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

Cellectis' rule of 40 is (128%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cellectis' rule of X is (150%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Cellectis Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Cellectis M&A Activity

Cellectis acquired XXX companies to date.

Last acquisition by Cellectis was on XXXXXXXX, XXXXX. Cellectis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Cellectis Investment Activity

Cellectis invested in XXX companies to date.

Cellectis made its latest investment on XXXXXXXX, XXXXX. Cellectis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).